manag attend healthcar corpor day last
week manag maintain origin guidanc
top line growth year despit tpiao alreadi achiev
growth ytd accord sampl sale data
launch bydureon two week ago first weekli
diabet china cost competitor
victoza novo nordisk daili price
day usag alreadi cover ndrl diabet
drug expect contribut profit
ipterbin herceptin nda new drug applic cfda
submiss month like get approv
howev unlik drug would get insur coverag
immedi new biolog drug categori
rais ep factor stronger-
than-expect tpiao sale growth rais tp
repres price-to-earnings believ current price
alreadi factor near-term growth compani pipelin
thin near mid-term maintain neutral
estimate pot chg tp
 chang prev ep
note lead manufactur biolog drug china rank term sale
recombin protein drug
click detail financi
launch bydureon first market long-last weekli
dose china compani believ larg market
potenti china given famili
market share diabet drug market could increas
five time compar penetr rate global market
contract eli lilli last year
gener
mn sale
howev see inclus drug caus pressur
market potenti competitor victoza novo nordisk
daili price per dose half month
usag alreadi cover ndrl list victoza pocket
cost around per month much lower bydureon
rel conserv bydureon sale given ndrl inclus
drug victoza
reappli ipterbin nda
compani go hand ipterbin breast cancer drug
nda new drug applic cfda month like take
cfda around year approv impli drug could
launch blockbust drug
clinic privileg origin drug global sale
compani withdrew ipterbin nda clinic data self-
investig estim success rate ipterbin approv
compani re-submit applic past two year
player caught ipterbin biosimilar develop
henliusfosun pharma subsidiari enter clinic trial phase
ipterbin biosimilar biosimilar applic categori
carri head-to-head studi roch origin drug
one strong competitor ipterbin launch
februari
surg tpiao yisaipu sale ndrl inclus
tpiao reimburs restrict loosen new
thrombocytopen purpura
thrombocytopenia indic inclus expans
sale contribut itp manag
mention tpiao sale surg around yoy much better
compani origin guidanc market expect
cover
manag see promacta tpo small monoclon
approv china challeng tpiao sale promacta
could includ medic insur reimburs list given
promacta sell larg price premium chines patient
quit sensit medicin price need persuas take
besid compani also oral small monoclon tpo clinic
trial see promacta long-term challeng obviou
advantag term oral form
manag maintain guidanc yisaipu growth yoy
new drug bydureon surg tpiao sale strong yisaipu sale
main growth driver compani
rais tp maintain
rais compani ep factor
stronger-than-expect tpiao sale strong yisaipu growth
 team oper scale scientist compar
list new target price base dcf model
impli price-to-earnings maintain neutral compani
see current valuat factor near mid-term
catalyst risk ipterbin approv well
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
compani mention price
serena shao katherin fu niko liu certifi respect compani secur individu analyz view
express report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
price rate histori inc
signifi initi assumpt coverag
price rate histori co lli
signifi initi assumpt coverag
price rate histori shanghai fosun pharmaceut group co ltd
signifi initi assumpt coverag
price rate histori shanghai fosun pharmaceut group co ltd
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun octob canadian well european ra ting base stock total return
rel analyst coverag univers consist compani cover analyst within relev sector ou tperform repres
attract neutral less attract underperform least attract invest opport uniti latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri regio nal benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price rel
attract stock total return potenti within analyst coverag univers australian new zea land stock expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform wh ere less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap ne utral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cov er multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform clo seli correspond
